This article is more than 5 years old. Information may no longer be current.

ACCOMPLISH: Amlodipine/benazepril combo lowered CVD morbidity, mortality by 20%

Trial challenges current therapy guidelines.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Combination therapy of amlodipine and benazepril in single-tablet form was effective for the treatment of high-risk patients with hypertension, according to findings of the ACCOMPLISH trial.

Kenneth A. Jamerson, MD, professor of the department of Internal Medicine at the University of Michigan Health System, presented the ACCOMPLISH findings today.

The researchers randomly assigned patients (n=11,462) to a combination of amlodipine and benazepril or a combination of hydrochlorothiazide and benazepril. Patients were 55 years or older and had systolic blood pressure =160 mm Hg.

The results challenge the current guidelines and demonstrated that therapy with a combination of amlodipine and benazepril should be the initial therapy, according to Jamerson.

“If you use a combination of a calcium channel blocker and an ACE inhibitor, you get exquisite blood pressure control,” Jamerson said today at a press conference. “With the combination, we had better blood pressure control and cardiovascular disease was reduced by 20%.” – by Christen Haigh

For More Information:

• Jamerson KA, Weber MA, Bakris GL, et al. Avoiding cardiovascular events through combination therapy in patients living with systolic hypertension, the early termination of the ACCOMPLISH trial for efficacy. Session 407; ACC 57th Annual Scientific Session; March 29-April 1, 2008.